M&A - SPRUCE BIOSCIENCES, INC.

Form Type: 8-K

Filing Date: 2025-04-15

Corporate Action: Acquisition

Type: New

Accession Number: 000095017025053944

Filing Summary: On April 15, 2025, Spruce Biosciences, Inc. issued a press release detailing its new corporate strategy and the acquisition of tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B. The company anticipates upcoming milestones and reported a cash balance of $38.8 million as of December 31, 2024. Additionally, a slide presentation outlining the acquisition was made available, which provides further insights into the corporate strategy concerning this therapy.